NovoCure Limited Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 5.09 M

NovoCure Limited Depreciation And Amortization is USD 5.09 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -53.98% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • NovoCure Limited Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 11.06 M, a 3.05% change year over year.
  • NovoCure Limited Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 10.73 M, a 2.33% change year over year.
  • NovoCure Limited Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 10.49 M, a 8.92% change year over year.
  • NovoCure Limited Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 9.63 M, a 14.41% change year over year.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased